Seminar
Navigating the Revised China’s Company Law
The German Centre Beijing, together with Rödl & Partner and CNBW held a hybrid seminar last Friday on navigating the Revised China Company Law.
Significant implications for companies operating in China
As discussed during the seminar, the revised law has significant implications for companies operating in China, necessitating adaptations for both domestic and foreign-invested entities. Of particular importance to foreign-invested companies is the alignment of the revised law with the expiration of a five-year adjustment period under the Foreign Investment Law by the end of December 2024. This underscores the urgency for compliance and proactive measures.
Key changes and recommendations for action to meet the implementation date Dec. 31, 2024
Sebastian Wiendieck, lawyer and partner of Roedl & Partner China, provided valuable insights during the seminar, highlighting key changes in the new Company Law. These include revised capitalization rules, organizational form, structure, participation of employee representatives, rules for share transfers, liabilities of senior management, and formalities. Additionally, Sebastian outlined a series of recommendations for what companies can do to meet the implementation date 31 December 2024.
German Centre Beijing – a platform for exchange of best practices from businesses for businesses.
If you have any further questions about China’s New Company Law or would like to discuss other relevant best practices for doing business in China, please don’t hesitate to reach out. Simply send us an email, and we’ll be more than happy to share our knowledge, provide advice, and connect you with the right partners.
Similar articles
More from German Centre Beijing
Digitales China (Teil II)
Verkehrsmittel, Online-Reisebuchungen, medizinische Dienstleistungen und ideale Orte für Geschäftstreffen stehen im Mittelpunkt des zweiten Teils unseres Leitfadens "Digitales China".
China Medtech
Start: 11.05.2023, 16:30 Uhr
Nehmen Sie an unserer Seminarreihe teil und erfahren Sie mehr über die Möglichkeiten für innovative deutsche Lösungen auf Chinas schnell wachsendem MedTech-Markt.